Interview With Rick G. CEO Abbvie Inc.

Discussion in 'AbbVie' started by anonymous, Jan 3, 2017 at 1:17 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    So over $2B traded between 9:30 a.m. and 4 p.m. Wednesday on U.S. exchanges at a volume-weighted average price of $102.02 based on the $105 Offer ? I smell a possible lawsuit by investors and could be SEC violation.
     

  2. anonymous

    anonymous Guest

    STOP SPREADING F'ING LIES !!!!!!!!!
     
  3. anonymous

    anonymous Guest

    THE ABOVE IS TOTAL BS!!!!!
     
  4. anonymous

    anonymous Guest

    Not a good sign !

    Dow Jones Industrial Average
    INDEXDJX: .DJI
    24,841.73 +206.52 (0.84%)

    AbbVie Inc
    NYSE: ABBV
    $97.87 USD −0.20 (0.20%)
     
  5. anonymous

    anonymous Guest

    Yes, we will hear more about this in the future.
     
  6. anonymous

    anonymous Guest

    So Rick orchestrated kickbacks to providers to RX Humira ? WOW, insurers paid $1.2 billion in fraudulent claims ? This is the largest health insurance fraud case the Department of Insurance has ever seen. Gonzalez illegally offered cash, meals, trips, drinks and patient referrals to physicians across California in order to ensure that they would continue prescribing Humira ? He sent RNs to patients HOMES under guise of patient care but in reality they were hiding patients side effects from Physicians ? How many other states did this occur in ?
    IT WASN'T JUST CALIFORNIA FOLKS.


    LOCK HIM UP !!!!!
     
  7. anonymous

    anonymous Guest

    Do you really think that Lil' Ricky had ANYTHING to do with that? Look a bit lower on the Food Chain to see who was responsible for that mess. Nobody can control everything, and Ricky was just probably away in Florida for that week...
     
  8. anonymous

    anonymous Guest


    Im in !!

    This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
    The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) AbbVie's strategy to increase the sales growth of its blockbuster drug, HUMIRA, was through illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would lead to heightened scrutiny by State governments and agencies; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

    A class action lawsuit has already been filed.
     
  9. anonymous

    anonymous Guest

    End of the gravy train appears to be in sight...
     
  10. anonymous

    anonymous Guest





    Investor suits against AbbVie pile up in wake of Humira kickback allegations
    Arlene Weintraub |
    Oct 11, 2018 11:24am

    Less than a month after California’s insurance commissioner sued AbbVie, alleging the company used kickbacks to boost sales of Humira, a second class action lawsuit has been filed on behalf of shareholders—and now, a raft of law firms is urging investors to join the fight.

    The latest filing, in AbbVie's home state of Illinois, comes on the heels of a similar suit filed in California. Law firm ___ LLP announced it sued AbbVie on behalf of shareholders who bought the company’s stock between October 2013 and September 2018. The suit stems from the California insurance case, which alleges AbbVie hired nurse “ambassadors” to go to patients’ homes and provide care related to Humira, a drug prescribed to treat rheumatoid arthritis and other autoimmune diseases. The company provided the nurses at no charge to physicians in exchange for Humira prescriptions, the suit alleges.


    AbbVie did not immediately respond to a request for comment about the Illinois suit. After the California shareholder case was filed, a spokesperson for the company said AbbVie believes the allegations are “without merit” and that the company’s nurses do not “replace or interfere with interactions between patients and their healthcare providers.”

    So far, AbbVie is winning the patent battle. Although biosimilar competition is hitting the European market now, the company has struck settlements that will keep cheaper rivals off the U.S. market until 2023.

    But now AbbVie has to grapple with aggrieved shareholders. In the past day alone, at least three law firms representing investors have sent alerts to their clients, urging them to join the class action lawsuits that have been filed against the company.
     
  11. anonymous

    anonymous Guest

    Who is driving the Humira biosimilar brand strategy? This is becoming highly transparent and very political now.
     
  12. anonymous

    anonymous Guest

    Besides the ADD fiasco, You folks remember how Rick screwed 16,000 HPD folks over while President of HPD division? How they were whacked to Newco Hospira for being a senior division? Targeted older demographic folks as HPD was the most senior division at Abbott? The 16,000 Fired Employees had class action ERISA suit with a 7 day bench trial in 7th circuit court. Abbott prevailed employees got nothing. Abbott and Ricky greased some judges and officials.They greased them so well Judge Gettleman praised and talked up Miles,Begley, Ricky and others. Corporate Greed by Rick and his Uncle Miles
    TISK TISK TISK
     
  13. anonymous

    anonymous Guest

    Marketing running constant TV spots.
     
  14. anonymous

    anonymous Guest

    Humira strategy is a legal strategy. Trump coming for it though.
     
  15. anonymous

    anonymous Guest

    Trump coming for Humira. Your lawyers built this house of cards, let’s see them get you out of it.
     
  16. anonymous

    anonymous Guest


    Company is in strong position for sure
     
  17. anonymous

    anonymous Guest

    Rick implemented a big shake up in C Suite with his direct reports.
    Alban to Chief Commercial Officer.
    Schumacher to Vice Chairman, External Affairs and Chief Legal Officer.
    Severino to Vice Chairman and President.
    Chase stays in current position until he leaves in Q219
    The reasons for this drastic shift will come out in 2019.

    Abbv
    84.33 USD −0.60 (0.71%)
     
  18. anonymous

    anonymous Guest

    Richard is stacking the deck for impending legal matters in 2019.
     
  19. anonymous

    anonymous Guest

    Rick is a member of Mensa, he is a certified genius. He is planning five steps ahead of everyone else in corporate HQ. A great man, a great leader, a great tactician, the Street loves him !
     
  20. anonymous

    anonymous Guest

    Looks like they are setting up for a major acquisition or merger.